| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 9, 2013System Available in U.S. and Canada
MINNEAPOLIS - April 9, 2013 - Medtronic, Inc. (NYSE:MDT) today announced market release of the CardioGuide(TM) Implant System, a novel real-time navigation system for cardiac resynchronization...
-
Apr 4, 2013Distinguishing Features of New Accessory for Endovascular Interventions Include Optimal Seal for Superior Hemostasis and Reinforced Coil for Proven Kink Resistance
MINNEAPOLIS -- April 4, 2013 -- Complementing its market-leading portfolio of stent grafts for the endovascular repair of aortic aneurysms and related conditions, Medtronic, Inc. (NYSE: MDT)...
-
Apr 2, 2013Medtronic Announces FDA Clearance and First Uses of New Oxygenation System for Adult Cardiac SurgeryNew System Designed for Patient Safety, Ease of Use During Open-Heart Procedures
MINNEAPOLIS - April 2, 2013 - Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the first U.S. clinical uses of its new Affinity Fusion®...
-
Mar 19, 2013
MINNEAPOLIS -- March 19, 2013 -- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $1.0 billion of its 1.375% Senior Notes due 2018, $1.25 billion of its 2.750% Senior Notes due...
-
Mar 11, 2013ACC.13 Presentation Features Unprecedented Data on Nearly 5,000 Patients, Including "All Comers," from Global RESOLUTE Clinical Program
SAN FRANCISCO -- March 11, 2013 -- Cardiologists at ACC.13 learned today that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) as...
-
Mar 10, 201324-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology
MINNEAPOLIS and SAN FRANCISCO - March 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal...
-
Mar 8, 2013
MINNEAPOLIS - Mar 8, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference on...
-
Mar 7, 2013IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic's Rigorous Global Clinical Trial Program for Hypertension Treatment
MINNEAPOLIS - March 7, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)...
-
Mar 6, 2013FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements
MINNEAPOLIS - March 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA)and the Centers for Medicare & Medicaid Services (CMS) have accepted the...
-
Mar 5, 2013New Lead Portfolio Provides Options for Physicians to Deliver CRT Optimally and Efficiently
MINNEAPOLIS - March 5, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark and will begin the European launch of the Attain Performa® portfolio of...
-
Mar 4, 2013Interruption or Discontinuation After One Month Following Implant Procedure Posed 'Low and No Increased Risk' of Stent Thrombosis at One Year in Clinical Studies
MINNEAPOLIS -- March 4, 2013 -- Of relevance to the clinical practice of interventional cardiology, Medtronic, Inc. (NYSE: MDT) announced today that it has received regulatory approval to update...
-
Mar 4, 2013"Global Heroes" Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October
MINNEAPOLIS - March 4, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the eighth annual...
-
Feb 28, 2013New Valve Provides Transapical Option for Physicians Treating Patients with Aortic Stenosis
MINNEAPOLIS - February 28, 2013 - Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européenne) Mark of the Engager Transcatheter Aortic Valve Implantation (TAVI) System with...
-
Feb 28, 2013
MINNEAPOLIS - Feb. 28, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Cowen and Company 33rd Annual Healthcare...
-
Feb 27, 2013Authors Reach Conclusions After a Meta-Analysis of 7 Clinical Studies for Snoring, and 7 Studies for OSA
MINNEAPOLIS - Feb. 27, 2013 - In a meta-analysis of seven studies published in the January issue of Laryngoscope, Ji Ho Choi, M.D., Ph. D., and coauthors conclude that the Medtronic Pillar...
-
Feb 26, 2013Shared Commitment to Innovation Enables Early Study of Novel Native Outflow Tract Transcatheter Pulmonary Valve in Patients with Pulmonary Valve Failure
MINNEAPOLIS - February 26, 2013 - Medtronic, Inc. (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval to conduct an early feasibility study using the...
-
Feb 25, 2013New Sizes of Implantable Medical Device Target Long Coronary Lesions Common Among Diabetes Patients
MINNEAPOLIS -- Feb. 25, 2013 -- Expanding the applicability of its marquee product for the interventional treatment of coronary artery disease in the United States, Medtronic, Inc. (NYSE: MDT)...
-
Feb 25, 2013
MINNEAPOLIS - Feb. 25, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Citi Global Healthcare Conference on...
-
Feb 19, 2013Revenue of $4.0 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS - February 19, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2013, which ended January 25, 2013. The Company reported...
-
Feb 14, 2013
MINNEAPOLIS - February 14, 2013 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the Company's common stock. The dividend is payable on...
-
Feb 13, 2013Second-generation MR-Conditional Pacemaker Combines Advanced Pacing Technology with MRI Access
MINNEAPOLIS - February 13, 2013 - Showcasing its leadership position in pacing technologies, Medtronic, Inc. (NYSE: MDT), today announced the U.S. Food and Drug Administration (FDA) approval and...
-
Feb 13, 2013The AIRvance(TM) Bone Screw System Is Now Suitable for the Performance of a Hyoid Suspension Procedure, Which Can Be Used in Combination with Other Procedures for the Treatment of Obstructive Sleep Apnea
MINNEAPOLIS - Feb. 13, 2013 - Medtronic announced today that it has received Food and Drug Administration (FDA) clearance for its AIRvance(TM) Bone Screw System that allows surgeons to perform a...
-
Feb 11, 2013
MINNEAPOLIS - Feb. 11, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2013 on Tuesday, February 19, 2013. A news...
-
Feb 5, 2013Rubio ayuda a los visitantes de la página web a salvar una vida "virtual" en HeartRescueNow.com
MINNEAPOLIS, 5 de febrero, 2013 - Ricky Rubio, la estrella de los Minnesota Timberwolves se une a la fundación Medtronic durante este mes de febrero para salvar la vida de jóvenes de todo el...
-
Feb 4, 2013Next-Generation ICDs Offer Patients Proven Treatment Performance, Increased Longevity, Improved Comfort
MINNEAPOLIS - February 4, 2013 - Medtronic today announced CE (Conformité Européenne) Mark of the Evera® portfolio of implantable cardioverter-defibrillators (ICD). With increased longevity and...